NCT02397694 - Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 23, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

February 27, 2019

Conditions

HIV-1 Infection

Interventions

DRUG

BIC

75 mg tablet administered orally once daily

DRUG

F/TAF

200/25 mg FDC tablet administered orally once daily

DRUG

DTG

50 mg tablet administered orally once daily

DRUG

BIC Placebo

Tablet administered orally once daily

DRUG

DTG Placebo

Tablet administered orally once daily

DRUG

B/F/TAF

50/200/25 mg FDC tablet administered orally once daily

Trial Locations (21)

20009

Washington D.C.

20036

Washington D.C.

22003

Annandale

30033

Decatur

30312

Atlanta

32803

Orlando

33316

Fort Lauderdale

33401

West Palm Beach

48072

Berkley

75208

Dallas

75605

Longview

77004

Houston

77098

Houston

78705

Austin

85012

Phoenix

90036

Los Angeles

90069

Los Angeles

95817

Sacramento

98104

Seattle

02115

Boston

07102

Newark